N-n-Butyl Haloperidol Iodide Ameliorates Cardiomyocytes Hypoxia/Reoxygenation Injury by Extracellular Calcium-Dependent and -Independent Mechanisms

Table 1

Effects of F₂, Verapamil, and ERK1/2 inhibitors and activator on cTnI level and cell viability in extracellular-calcium-containing myocardial H/R (𝑛=9).

Group	cTnI (ng/mL)	Survival rate (%)
CaCon	0.22 ± 0.01	100.00
CaH/R	0.61 ± 0.03*	47.51 ± 2.15*
CaH/R + F2	0.49 ± 0.02^*#	64.23 ± 2.78^*#
CaH/R + U0126	0.50 ± 0.03^*#	63.52 ± 2.46^*#
CaH/R + PD98059	0.48 ± 0.02^*#	60.40 ± 2.21^*#
CaH/R + Ver	0.47 ± 0.02^*#	56.85 ± 2.24^*#
CaCon + EGF	0.22±0.01^#†	93.34±3.91^#†
CaH/R + F2 + EGF	0.59±0.01^∗†	48.54±3.56^∗†

F₂, N-n-butyl haloperidol iodide; cTnI: cardiac troponin I; H/R: hypoxia/reoxygenation. *𝑃<0.05 versus CaCon group; ^#𝑃<0.05 versus CaH/R group; ^†𝑃<0.05 versus CaH/R + F₂ group.